Virtual Library

Start Your Search

L. Qian



Author of

  • +

    Poster Session (ID 8)

    • Event: ACLC 2018
    • Type: Poster Session
    • Track:
    • Presentations: 2
    • Moderators:
    • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
    • +

      P043 - Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer (ID 35)

      00:00 - 00:00  |  Author(s): L. Qian

      • Abstract

      Background:
      Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is clinically effective as a first-line and second-line therapy in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). Use of this treatment is limited by high costs. Here, we conducted a cost-effectiveness analysis of different sequences of osimertinib administration in China and the United States.


      Method:
      We established Markov models based on data from the FLAURA and AURA3 trials, which included patients with EGFR mutation-positive advanced NSCLC. The cost-effectiveness analysis compared first-line osimertinib to first-generation EGFR-TKIs or second-line osimertinib after the failure of first-generation EGFR-TKIs. The analysis also considered different payment modalities available in China. Additionally, we performed 1-way sensitivity and probability sensitivity analyses with a willingness-to-pay threshold (WTP) of 3

    • +

      P044 - Cost-Effectiveness Analysis of Icotinib vs Whole-Brain Irradiation in NSCLC Patients with Brain Metastases (ID 122)

      00:00 - 00:00  |  Author(s): L. Qian

      • Abstract

      Background:
      Non-small-cell lung cancer (NSCLC) patients with brain metastases had a poor prognosis and quality of life. Despite the traditional methods including radiotherapy and chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) might benefit patients on survival and quality of life. We investigated the cost-effectiveness of icotinib compared with WBI with or without chemotherapy for NSCLC patients with brain metastases.


      Method:
      A markov model was conducted based on the data of BRAIN trial. We compared the economic benefit among icotinib, whole-brain irradiation (WBI) alone group, WBI plus chemotherapy group, and the combination of WBI and WBI plus chemotherapy group. We considered disease progression as intracranial progression and overall progression separately. Sensitivity analyses were performed to observe the stability of the model. The willingness-to-pay (WTP) was set as 3